Literature DB >> 17384656

Surgical resection of persistent pulmonary fungus nodules and secondary prophylaxis are effective in preventing fungal relapse in patients receiving chemotherapy or bone marrow transplantation for leukemia.

A Nosari1, M Ravini, R Cairoli, P Cozzi, L Marbello, P Marenco, G Grillo, E Morra.   

Abstract

Antifungal therapy may be unable to eradicate invasive mycosis in leukemia patients. The presence of persisting pulmonary nodules owing to mycosis seems to increase the risk of fungal relapse after chemotherapy and transplant procedures. Between 1997 and 2004, 10 acute leukemia patients underwent pulmonary surgery for invasive mycosis. The median time from diagnosis of mycosis to surgery was 135 days (range 21-147). Three patients underwent emergency surgery, owing to hemoptysis. In the other seven patients with nodule/cavitation remaining after antifungal treatment, surgery (three wedge resections, four lobectomies) was scheduled before transplant. Pathologic examination confirmed two aspergillosis and three zygomycosis. The only side effect was pneumothorax in one case. Nine patients were considered cured. Six patients underwent bone marrow transplantation (three allogeneic, three autologous) with antifungal prophylaxis without relapse during the transplant procedure. In selected patients scheduled for bone marrow transplantation, surgical resection of localized pulmonary fungus nodules combined with antifungal prophylaxis seem to be an effective treatment for preventing mycotic relapse.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17384656     DOI: 10.1038/sj.bmt.1705655

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  5 in total

1.  Secondary Antifungal Prophylaxis in Hematopoietic Stem Cell Transplantation (HSCT)/Acute Leukemia Patients.

Authors:  Jean El Cheikh
Journal:  Curr Infect Dis Rep       Date:  2011-12       Impact factor: 3.725

2.  Secondary antifungal prophylaxis in hematological malignancies in a tertiary medical center.

Authors:  Axia Song; Dong-Lin Yang; Yong Huang; Er-Lie Jiang; Zhang-Song Yan; Jia-Lin Wei; Mei Wang; Qiao-Ling Ma; Yi He; Rong-Li Zhang; Wei-Hua Zhai; Si-Zhou Feng; Ming-Zhe Han
Journal:  Int J Hematol       Date:  2010-12-03       Impact factor: 2.490

3.  Weekly liposomal amphotericin B as secondary prophylaxis for invasive fungal infections in patients with hematological malignancies.

Authors:  Lizbeth Cahuayme-Zuniga; Russell E Lewis; Victor E Mulanovich; Dimitrios P Kontoyiannis
Journal:  Med Mycol       Date:  2011-11-22       Impact factor: 4.076

4.  Invasive pulmonary fungal infection accompanied by severe hemoptysis in patients with hematologic diseases: a report of nine cases.

Authors:  Lei Qiu; Jingsong He; Xiujin Ye; Wanzhuo Xie; Jimin Shi; Weiyan Zheng; Jie Sun; Xiaoli Zhu; Zhen Cai; He Huang; Maofang Lin
Journal:  Int J Hematol       Date:  2009-05-30       Impact factor: 2.490

5.  Treatment of invasive fungal infections in cancer patients-updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).

Authors:  Sabine Mousset; Dieter Buchheidt; Werner Heinz; Markus Ruhnke; Oliver A Cornely; Gerlinde Egerer; William Krüger; Hartmut Link; Silke Neumann; Helmut Ostermann; Jens Panse; Olaf Penack; Christina Rieger; Martin Schmidt-Hieber; Gerda Silling; Thomas Südhoff; Andrew J Ullmann; Hans-Heinrich Wolf; Georg Maschmeyer; Angelika Böhme
Journal:  Ann Hematol       Date:  2013-09-12       Impact factor: 3.673

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.